LGND
Ligand Pharmaceuticals Incorporated
NASDAQ: LGND · HEALTHCARE · BIOTECHNOLOGY
$232.55
+0.11% today
Updated 2026-05-06
Market cap
$2.76B
P/E ratio
37.04
P/S ratio
10.29x
EPS (TTM)
$6.14
Dividend yield
—
52W range
$99 – $247
Volume
0.2M
WallStSmart proprietary scores
71
out of 100
Grade: B
Buy
Investment rating
9.3
Growth
A+8.5
Quality
A7.5
Profitability
B+6.0
Valuation
B4/9
Piotroski F-Score
Moderate
6.4
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →197 stocks currently score above 75
Price targets
Analyst target
$268.00
+15.24%
12-Month target
$185.80
-20.10%
Intrinsic (DCF)
$272.20
Margin of safety
+31.68%
2 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 6.43 — safe zone
+ Profit margin 46.40% — above average
+ Free cash flow $45.84M — positive
+ Revenue growth 39.40% QoQ
+ 31.68% below intrinsic value
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $196.25M | $131.31M | $167.13M | $268.09M | $268.09M |
| Net income | $-33.36M | $52.15M | $-4.03M | $124.45M | $44.78M |
| EPS | — | — | — | — | $6.14 |
| Free cash flow | $119.93M | $-4.27M | $77.41M | $48.91M | $45.84M |
| Profit margin | -17.00% | 39.72% | -2.41% | 46.42% | 46.40% |
Peer comparison
Smart narrative
Ligand Pharmaceuticals Incorporated trades at $232.55. representing a P/E of 37.04x trailing earnings. Our Smart Value Score of 71/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 6.43, it sits in the safe zone. TTM revenue stands at $268.09M. with profit margins at 46.40%. Our DCF model estimates intrinsic value at $272.20.
Frequently asked questions
What is Ligand Pharmaceuticals Incorporated's stock price?
Ligand Pharmaceuticals Incorporated (LGND) trades at $232.55.
Is Ligand Pharmaceuticals Incorporated overvalued?
Smart Value Score 71/100 (Grade B, Buy). DCF value $272.20.
What is the price target of Ligand Pharmaceuticals Incorporated (LGND)?
The analyst target price is $268.00, representing +15.2% upside from the current price of $232.55.
What is the intrinsic value of Ligand Pharmaceuticals Incorporated (LGND)?
Based on our DCF model, intrinsic value is $272.20, a +31.7% margin of safety versus $232.55.
What is Ligand Pharmaceuticals Incorporated's revenue?
TTM revenue is $268.09M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
6.43 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.29x
ROE13.50%
Beta1.00
50D MA$210.35
200D MA$187.07
Shares out0.01B
Float0.02B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—